Philippe Menu Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $8.68, for a total value of $43,400.00. Following the sale, the insider directly owned 213,387 shares in the company, valued at $1,852,199.16. This trade represents a 2.29% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total value of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.66, for a total transaction of $28,300.00.
• On Monday, July 13th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.70, for a total transaction of $28,500.00.
• On Monday, July 6th, Philippe Menu sold 7,393 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.16, for a total value of $38,147.88.
• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.50, for a total value of $27,500.00.

SOPHiA GENETICS Price Performance

SOPH stock opened at $8.92 on Friday. The company has a market capitalization of $748.34 million, a P/E ratio of -7.76 and a beta of 0.96. SOPHiA GENETICS SA has a twelve month low of $3.10 and a twelve month high of $8.98. The business has a 50 day simple moving average of $6.46 and a 200-day simple moving average of $5.43. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analyst estimates of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. As a group, equities analysts anticipate that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares during the last quarter. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS during the second quarter valued at approximately $9,809,000. Akre Capital Management LLC lifted its holdings in SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after buying an additional 1,481,636 shares during the last quarter. Hodges Capital Management Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter valued at approximately $2,157,000. Finally, Royce & Associates LP acquired a new position in SOPHiA GENETICS in the fourth quarter worth $2,009,000. 31.59% of the stock is owned by institutional investors and hedge funds.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Unusual trading volume is drawing attention to SOPH, with the stock approaching a new 12-month high. The activity suggests increased investor interest and reinforces the recent upward momentum. When Unusual Volume Isn’t Noise: 3 Small-Caps Sending Signals
• Positive Sentiment: Analyst sentiment improved after the August 5 earnings report. BTIG Research raised its price target to $9 from $8, while HC Wainwright lifted its target to $14 from $12; both firms maintained Buy ratings. The reported $23.31 million in revenue exceeded the $21.72 million consensus estimate, although the company still posted a larger-than-expected quarterly loss. The average analyst price target is approximately $10.
• Neutral Sentiment: Reported short interest was zero shares as of August 25, indicating little measurable short-selling pressure, but also providing limited incremental trading information.
• Negative Sentiment: Several insiders recently sold shares: CTO Abhimanyu Verma sold 5,000 shares on August 19 and another 5,000 on August 24; Director Kathy L. Hibbs sold 6,250 shares on August 25; and Philippe Menu sold 5,000 shares on August 25. The transactions reduced their individual holdings by roughly 2% to 6% and could weigh on sentiment. However, all were executed under pre-arranged Rule 10b5-1 plans, meaning they may not represent current concerns about SOPHiA GENETICS. SEC insider transaction filing
• Negative Sentiment: SOPHiA GENETICS remains unprofitable: it reported a quarterly loss of $0.26 per share versus the $0.21 consensus loss estimate, and analysts expect a full-year loss of approximately $0.77 per share. Its negative margins and continued earnings losses remain key risks despite the revenue beat and improving share-price momentum.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on SOPH shares. Zacks Research upgraded shares of SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research raised their target price on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. HC Wainwright raised their price target on SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.